A 24-year-old shares 4-month progress using finasteride, minoxidil, and microneedling for hair loss. They report positive results and plan to update in a few months.
Hair cloning is discussed, focusing on its current status and potential availability. Treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation is about starting a hair loss treatment using a topical solution containing RU58841, Minoxidil, and Copper Peptides. The user plans to test the product and share updates on its effectiveness.
Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.
PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.
Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.
The user experienced significant hair regrowth using finasteride 1mg daily, minoxidil 5% twice a day, and microneedling 3-4 times a week. They reported no side effects from finasteride and are pleased with the results, feeling more confident and maintaining a new hair baseline.
User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.
PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.
A user shared their impressive hair regrowth progress after 5 months using 1mg oral finasteride every other day, 2.5mg oral minoxidil daily, weekly dermastamping, and daily scalp massages. They reported no side effects and began seeing improvement after 2.5 months.
PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.
PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.
The user has been using Minoxidil, Finasteride, and biotin for hair regrowth over four years, recently adding microneedling with a derma pen. They are considering increasing microneedling frequency, trying minoxidil pills, and possibly using Dutasteride for better results.
User tried oral dut 0.5mg, oral min 5mg, topical RU 80mg, and weekly microneedling at 1.5mm for hair loss. Others commented on the significant improvement and potential for future hair transplant.
The conversation discusses the progress and potential of hair cloning by Stemson Therapeutics, questioning if it will be realized in the next 5-10 years or if it's just false hope. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
Han Bio plans to start clinical trials for a new hair multiplication technology this year, which could significantly reduce the cost and time of hair transplantation. The technology uses a single hair strand to cultivate enough cells for 30,000 hair strands.
RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.
Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.
The user reports progress in hair regrowth using topical finasteride/minoxidil, microneedling, topical dutasteride, latanoprost, and MSM supplements. They express frustration over the lack of interaction on progress posts compared to trivial topics.
PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.
The conversation discusses hair loss treatments, specifically seeking a trusted supplier for RU58841. Minoxidil and finasteride are also mentioned as treatments.
The user shared progress pictures of their hair growth after using finasteride, oral minoxidil, and undergoing a hair transplant with 4,200 grafts in Istanbul. They reported thicker hair and noticeable crown regrowth, with no side effects from the treatments.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. Concerns are raised about the lack of studies on RU58841 and its potential effects.
CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.
RU58841 is discussed for hair loss treatment, with questions about its legitimacy from RUdirect. Minoxidil and finasteride are also mentioned as treatments.